Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Advertisement
No AccessJournal of UrologyAdult Urology1 May 2018

Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study

View All Author Information

Purpose:

We compared blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance.

Materials and Methods:

Patients at high risk for recurrence received hexaminolevulinate intravesically before white light flexible cystoscopy and randomization to blue light flexible cystoscopy. All suspicious lesions were documented. Patients with suspicious lesions were referred to the operating room for repeat white and blue light cystoscopy. All suspected lesions were biopsied or resected and specimens were examined by an independent pathology consensus panel. The primary study end point was the proportion of patients with histologically confirmed malignancy detected only with blue light flexible cystoscopy. Additional end points were the false-positive rate, carcinoma in situ detection and additional tumors detected only with blue light cystoscopy.

Results:

Following surveillance 103 of the 304 patients were referred, including 63 with confirmed malignancy, of whom 26 had carcinoma in situ. In 13 of the 63 patients (20.6%, 95% CI 11.5–32.7) recurrence was seen only with blue light flexible cystoscopy (p <0.0001). Five of these cases were confirmed as carcinoma in situ. Operating room examination confirmed carcinoma in situ in 26 of 63 patients (41%), which was detected only with blue light cystoscopy in 9 of the 26 (34.6%, 95% CI 17.2–55.7, p <0.0001). Blue light cystoscopy identified additional malignant lesions in 29 of the 63 patients (46%). The false-positive rate was 9.1% for white and blue light cystoscopy. None of the 12 adverse events during surveillance were serious.

Conclusions:

Office based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and it is safe when used for surveillance. Blue light cystoscopy in the operating room significantly improves the detection of carcinoma in situ and detects lesions that are missed with white light cystoscopy.

References

  • 1 : A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol2004; 45: 539. Google Scholar
  • 2 : 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int2005; 96: 798. Google Scholar
  • 3 : Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol2005; 174: 2129. LinkGoogle Scholar
  • 4 : Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol1991; 146: 316. Google Scholar
  • 5 : [ALA fluorescent diagnosis of bladder cancer]. Urologiia2000; 5: 48. Google Scholar
  • 6 : The value of secondary transurethral resection for superficial bladder tumors. Akt Urol1994; 25: 208. Google Scholar
  • 7 : The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol1998; 22: 1435. Crossref, MedlineGoogle Scholar
  • 8 : Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. J Photochem Photobiol B2002; 76: 518. Google Scholar
  • 9 : Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B1990; 6: 143. Crossref, MedlineGoogle Scholar
  • 10 : A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol2007; 178: 62. LinkGoogle Scholar
  • 11 : Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer. J Urol2010; 184: 1907. LinkGoogle Scholar
  • 12 : Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int2011; 108: E297. Google Scholar
  • 13 : Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. J Endourol2009; 23: 977. Google Scholar
  • 14 : Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol2011; 52: 123. Google Scholar
  • 15 : A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol2007; 178: 68. LinkGoogle Scholar
  • 16 : Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol2012; 188: 58. LinkGoogle Scholar
  • 17 : Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol2013; 64: 624. Google Scholar
  • 18 : Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol2013; 64: 846. Google Scholar
  • 19 : Clinical and cost effectiveness of hexaminolevulinate-guided blue light cystoscopy: evidence review and updated expert recommendations. Eur Urol2014; 66: 863. Google Scholar
  • 20 : The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol2013; 20: 6682. Google Scholar
  • 21 : World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC2004. Google Scholar
  • 22 : AJCC Cancer Staging Handbook, 7th ed. New York: Springer2010. Google Scholar
  • 23 : Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?. Eur Urol2005; 47: 323. Google Scholar
  • 24 : Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline, 2016. Available at https://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm. Accessed November 1, 2017. Google Scholar
  • 25 : Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol2014; 11: 589. Google Scholar
  • 26 : Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. Urology2014; 84: 122. Google Scholar